MCM7

Across TCGA pan-cancer cohorts, MCM7 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MCM7 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MCM7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MCM7 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, HNSC, and SKCM are the cancer types where MCM7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.042	0.781	<.001	30	view →
HNSC	OS	Median	II,III,IV	0.343	0.745	<.001	29	view →
SKCM	DFS	Median	III,IV	0.235	0.623	<.001	11	view →
UCEC	DFS	Median	II,III,IV	1.000	0.444	.030	8	view →
LUAD	OS	Median	All	0.188	0.670	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MCM7–LIHC (OS)

Open the LIHC breakdown →